Search bioRxiv⌕ Search

Biology subjects

Adegboro, A. A.

Publications and source records attributed to Adegboro, A. A..

2 recordsLinked to original sources

Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection

With the widespread use of high-throughput sequencing technologies, understanding biology and cancer heterogeneity has been revolutionized. Recently, several machine-learning models based on transcriptional data have been developed to accurately predict patients outcome and clinical response. However, an open-source R package covering state-of-the-art machine learning algorithms for user-friendly access has yet to be developed. Thus, we proposed a flexible computational framework to construct machine learning-based integration model with elegant performance (Mime). Mime streamlined the process of developing predictive models with high accuracy, leveraging complex datasets to identify critical genes associated with prognosis. An in silico combined model based on de novo PIEZO1-associated signatures constructed by Mime demonstrated high accuracy in predicting outcomes of patients compared with other published models. In addition, PIEZO1-associated signatures could also precisely infer immunotherapy response by applying different algorithms in Mime. Finally, SDC1 selected from PIEZO1-associated signatures presented high-potential role in glioma with targeted prospect. Taken together, our package provides a user-friendly solution for constructing machine learning-based integration models and will be greatly expanded to provide valuable insights into current fields.

bioinformatics↗

Machine learning-based investigation of regulated cell death for predicting prognosis and immunotherapy response in glioma patients

BackgroundGlioblastoma is a highly aggressive and malignant type of brain cancer that originates from glial cells in the brain, with a median survival time of 15 months and a 5-year survival rate of less than 5%. Regulated cell death (RCD) is the autonomous and orderly cell death under genetic control, controlled by precise signaling pathways and molecularly defined effector mechanisms, modulated by pharmacological or genetic interventions, and plays a key role in maintaining homeostasis of the internal environment. The comprehensive and systemic landscape of the RCD in glioma is not fully investigated and explored. MethodAfter collecting 18 RCD-related signatures from the opening literatures, we comprehensively explored the RCD landscape, integrating the multi-omics data, including large-scale bulk data, single-cell level data, glioma cell lines, and proteome level data. We also provided a machine learning framework for screening the potentially therapeutic candidates. ResultHere, we explored RCD-related phenotypes, investigated the profile of the RCD, and developed a RCD gene pair scoring system, named RCD.GP signature. Using the machine learning framework consisting of Lasso, RSF, XgBoost, Enet, CoxBoost and Boruta, we identified seven RCD genes as potential therapeutic targets in glioma and verified the SLC43A3 by q-PCR in glioma grades and glioma cell lines. ConclusionOur study provided comprehensive insights into the RCD roles in glioma, developed a robust RCD gene pair signature for predicting the prognosis of glioma patients, constructed a machine learning framework for screening the core candidates and identified the SLC43A3 as an oncogenic role and a prediction biomarker in glioblastoma.

bioinformatics↗